Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.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?oc=5" target="_blank">Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
When will 2027’s Social Security COLA be announced?
Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável
Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’
James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5pRFBqVk9LODZlUWxMVXJlN3RSMllQeWFFLXdFclAyZEQxQjc5NVFod1NCMEo4VTNlQy1SN1VQR2htQW9oekx1SzVxNHVwU1NfTXFmSGtUZHh2d2s?oc=5" target="_blank">BHVN News | BIOHAVEN LTD (NYSE:BHVN)</a>&nbsp;&nbsp;<font color="#6f6f6f">ChartMill</font>
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxORUFxb2RXeWJiVjlxVVozSTdvQS1mLVZaM2lGZ2d2ZHpWOHlkcmMzbWZadGNoZWg5M184RUxFbHI1bW5QUHEwYjdMODBaUWxacWZfZmJzSVVrTGZSU1pnQ2ozQ0EwRmEyWmVJZEgxdENrX2xTNzVSVWw4TVdDb1U2OHBvZDdtcGRWeXl5RGZTbGZGTzk3WXhHRlRCYi1BeHVONGVOemVfRHUzempyQm5TWXFJZEtfeVZRR0p6SDdLWFJ1elRobTd1akRjTFdtcFZDUllSVDNob1V6NTA?oc=5" target="_blank">Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxONkc3MXVxUmtNclM2SUpxbU9aWEdfUkVacGhpdGhpdVhrM3dtTjdtV0luRVdBSnlQNFR5RkkyMTJTSHZOOHRxWEJfZ1ZrNjhZQ2ZwNW10R1VaaXpKZkxEanc4TmtkVVNraG9CQnJIODFDNmJYY1JqLXgtNS1VYUdCbzZUNElXWG13ZXdCam1GaEY1U0ZJeExURw?oc=5" target="_blank">Why Biohaven Stock Was Rocking the Market This Week</a>&nbsp;&nbsp;<font color="#6f6f6f">The Motley Fool</font>
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOYkY2bl83TGlNTEppUkRBNGJNRzJIaXJ3bVd2QmVOZTh0SU1QYXlhbUJlRVBXcTNHUGhET2oxdm9tNktkTU1oUnNfVlY0RVBSNkRQVnhiXzFCZGxhVzZGcFh0bG9TekJZZnJvWnFGbXQ5WHlJdkhjcUp6OC0wcnlsRGJDVm1jM0x0SDJWelZhNlJqbUJPeGJxR05RNGV6alpQckxjNkZ1R3JGUUE5dzFBcVFBYkUtY0RKY0tXNE5SX1pMSjRwQnczbjl1RGdfSmtwZDRKeVN4MFdqejBfWUE?oc=5" target="_blank">Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference</a>&nbsp;&nbsp;<font color="#6f6f6f">Lelezard</font>
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOZ3I2SEd0YzNpRFRITC15NmFRNEZ4eUVoRzFrY3pwbUVLZnRKS0ozdGVveTFrWFR1WUxZM1kyaGxLeDhxaGg4bGtCWFVYY1NSZUl0WkJ1a1R1eGdfWHNmSDhkU1B1QmJXN1k5QjB6OHY4TjkySUFleWJiTlFwODlmTWZBYW1GaU5waGdPT3dVVUxkd1UwNzVSZkZhWF9tWDRHd2VoaWVaOEw5OVdMNFYwUzN3?oc=5" target="_blank">Biohaven stock jumps on positive drug trial results By Investing.com</a>&nbsp;&nbsp;<font color="#6f6f6f">Investing.com UK</font>
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNZFFxcl9WUU9WWmJSSHVJdGR1R0xxX0ttcHJtU0tmSW1FRVRmSVFGcEM3MThJc2VJRFVvYUIzSGZJZm1UMGJJakpPUXJqZmZJWThwb2VGeG1neERTV2hkQXhkTEF1YUE3THN3T0VHeDZYRXRybTZCNnoxQjJvVjVyUTdQb3l1ck50MEktRG5SWXFNaVpEdTRraXY4VUVnLXN4dlVEaGNGVjRiVTZ0SHJzanJ4RXAtYTZrWlJHZWxuUEFTa1J3a0lzSENTcWdLWGVBcldYdHBNeDNlcThQc1doMjd4bTJMNXFfd1JHU253?oc=5" target="_blank">Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5oWVkyaGdoRVVSbl9wZUFoM2FWeldxOENEbjMxSEFEb3hvTnRIakZkQ3BiUEc3VVE5MHdZMVA1ZFFkeU02NXdDSFYzdTV6bTJ4YzNDRG02Q0xKRGVSV1dJWGxtTFRrRjJ3Z1QtU1dxTV93Q2Q1Mi05cg?oc=5" target="_blank">Biohaven Details Pipeline Update At JP Morgan Conference</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Executive</font>
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQSEtqWVhvb0wwRjJmN0VHY3BxSVM1UnpGUDVsR1VXTWFMdThHN0VIMGJTbWtuMm5uYUxvNUNHOW9LRjJUZFAtRHlicG40OE5qaUtFMVFxb3ZiZGhDdS1PTXJ1ekdqbWxTWnM3TWh5WE4wR1l0QjhnQmNTUmthTjhIZVNZNm5Oc1hIQ3NZeQ?oc=5" target="_blank">bhvn-20240630</a>&nbsp;&nbsp;<font color="#6f6f6f">SEC.gov</font>
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPS2Fzc2IyUEhac0VFaXdkQXFYZ2hURkFJZTBKaTVONk00ZWl0YUZsMnM2bW5FMV96YTB1TWF2bGJMYUJqRTRKaF8wcXJLV1UtZ1F3RFRPcFlVcUE4Ml8tQlJjQ3gtUlpiekI4WldpTFhKODU5UWR3OGJ4V0FxeGx2U0VJeGlGYkRYcEJudk0xM0xUeTJOZFFuNG1TMXhKUW1IVkh6VU5BU3o1T25uQVVub3dDYlk4dVd3T0VpLURtZ1hxSHM?oc=5" target="_blank">Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels</a>&nbsp;&nbsp;<font color="#6f6f6f">Seeking Alpha</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQY2FsYjRJS1JOLWxLd1ZoMTVHY1dRWVRIcVVaT1Nfem1jcGFEQnRGZnlKOFpUSkdZRTllT1p3c3IycmlOSEw1Smx1bFNwUnE2cTlfWnVhRnEzYjBSaVhCRVl1T0pucWZmTElTLVBwOGJLQ0JHbUJneTZGbWptY3FURWw1WnlNOE5hQXZWWnRYbktKc0YwSWFTam5JRkFudmVlcy1yZUdsQl9qLTBYZkpCS3ZnTkdRaEpXLW5MWHd2OUQ?oc=5" target="_blank">Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment</a>&nbsp;&nbsp;<font color="#6f6f6f">Stock Titan</font>
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxQU1NINUtTOXVwLW45a3VvcGdkcFFycjJaU1lVZnFjSXVvc3duZnlycG9Pa2NEdzFMU1hSdnpHREctUkF3OXhRWks2TXBXVDZfbFNQWU5wendfVkxySkh6QUNjbnhleXA4SEMzSHlhOVJPT0NhcnBYamNadFh6S2ZFMjNUYkpZaFh4LVZCdXlLOFA2ekxYWWJIRFlkbF9CekphUDNSckpHN2VLSWwzTGVXT0tKbzg0R0w0LUFoa21FNjZ2Y0RVVzFmZ1JmTC1oY1RMRzFxcmdZVHBBVlN0WFFyLXdQXzJ6Y1FmUUExV1B4cVI2bHdJOFFHMUJmRi1STjF5WV9IaWYzZ2UtTG9zTkVj?oc=5" target="_blank">Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.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?oc=5" target="_blank">Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.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?oc=5" target="_blank">Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNUGJackhQUVFoYU5rcmJBT2pKNTl1UnRZTV9Gbm5taWgxZTRGb0hLMEZzczBWT0ljQ1ZWZmwzNnJHcVQwbUNhQkhnNncxdWZMcXZnOUZXRDhvdWVwdGdwUlQwU18wRHZQcFlYZmt1MjByaUtOUnhrY2hMVXlfNVBrLTF0OXVIdGVqYkdaZEdDUkkycVMwOE5KY3E0N3BMUUJUa2tndjNiQm5jZ3dNaU1PQ09pNFZJMFVpaktyRnlqUjlKQlRManNJLUF2LS1hZkEwazJ1OE1SeXlhSEpmWEVweFZlVGs3VzNGUjFfcXlB?oc=5" target="_blank">Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPUmJvOHJzaUlvMWw4VTZMXzVCeHBOQ2FaS19lWkxGXzVFSFBXdnFKdHdoRXpfM1ZsdldtMWlZNVViOHlRNmc4SUt0NTBLZGpkU0tnYXVLZGFUYnlKbUNIRXdHQUdfaVhoOWVEQUdubWJSWDRmQ2w5ZGFIMEZzMW5NYktEY2ZKUmtEUk1CSVRnb2tDcS1OSGVXZFJZU2s2ODhsLXJvLWdKalFpODgybWRENzVMMnh3cEU1Y3EzRWQtVEZKOEJLMDlTNkh3OHFsOXF2d09Wb0xEbEIyU28?oc=5" target="_blank">Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.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?oc=5" target="_blank">Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMi6AJBVV95cUxNSExYR05ibi1YNWVldFRyRkQ3TGprNnYwSkZsRTlaZ1p5YUpZWFA3ai0zbV92djZWZE1DdmJoaU9KWk01UGxfdk53b3ZoRTNMUUlKeEZKRlVrQ2lVenc0VllMcE5sZWM5a09xMzRXMkpiYXA4d0lyMHNBbTZndnZsQzl3Z3pzVE1xSkl1V3N5ZUtfaWxsT0Q5LVdCN0FiRzlDZHZkdDAtenJCNTFrYWZEbkJOdzFyVDlQVnE5bUhXZ0J2Wk8zYXlhZWxiQ0tfbHVtMGFmVmN4Tl9mOXpCTzNfdk1iTXh6c2Z1bWtPa3YzdFphSWRmMGlXMk0tQXA3Rzc0eE53WGZNN0lLYTVucFZCV1V1SUYxWF9xemJId0dsRnJBdWxMS0I5cE1leXYzVmI0TV90TmU0bjhuSkFGMmVHMXU5Nm5qaXZtMU84S1VqWjVEbkE3dGlOTkI5TjlMMHhoNGZnZnd0NVc?oc=5" target="_blank">Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPNUQ1N3lQd3NKanV5TGFtUGJvRHU5TVo4N2dBa2lubjF0c3o0M3JkeTRnb0hJMi02cDFpdl9xNGJ6UUcyMGxJVGhVem5ERVZBQ3NtY09XUkk5Q01IQ3I2OG1uWnZOUDA3M0xQTGpxOExOR2hRbUNlX0QxVEEtOWwxLWlZcHpKTVB2RnVycGlmcUFPS3NzY0tXN1hpc2ExVU8yT1ZyUWxkeFFZWF9BX2E3RFJKZGs3eHA1Rk16Z2o1LW1PczFkUFlhOHVIOGNoc2RJWnNldjl0cUZnRzFtdWs1aGhBeHFBblZMd2JXazhn?oc=5" target="_blank">Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPcmNPWG92dEljeVdyREpwS0g0SFdFSnE2ajhyazI1dWpJTHF5WTN1SXNTenVpODVqMXdGUkYyLUNPcjYzWmlyTzBuazZfS2xrVmJOQy1oblpYLU1TZEJ6bHZiOUU5ei1tU1BQRFZUeDBJbVNWUVQ0bVdvTHF5RE1ibGd5ZFZwUFgzRGhSLVl5T3A2OElScFowS0hqVmpjVFFtanRkM2ZfbzNGa3VvbGl0dA?oc=5" target="_blank">Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>
<a href="https://news.google.com/rss/articles/CBMi8gJBVV95cUxPMWdhTVNodTBmbnZWLXA2OXlyMzc1T21VbVlpMlExZzJZSmptaTBVLTU3R0EybElfMklKeHhWdXdVa1laV2VvcUc0M1dGQ3d3cmw1bXRLSFc5eWNRVXdnOGhnN1AyM3BGcFdBRXNDN081Nm9EclJ3TGU2VlJPUFQ3am05TzYzb2lLTDFISWZXOGdYLTBBQnQ4YXNhWkpqRWoxZmZmUVJJeU5GSXp1LXF1RFlTdjAyT21BVjZfekx1WUQ1YWtuX3RubEdmU1V1Q2t3aHZPWmVoR3ZTWTZCR0tfbG9VazhHRVNIQW9URGpuYUVCV2E5eE9MY1Z6WHBZWFBnTjIxX0YxWm5RV1d6ODZOd3pSamdXTTlVSFpxMXYyOGdSampOQzloMnZxeHpOYzdZT3FFMm5wOEJkdXJ6Y0xLeklwVDZUUXhWb29xY1NPRURSWUszbWpodEx4WFYza19lUTZoYTR1WkxuNmlOMTZaSURn?oc=5" target="_blank">Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQaXl2aHZiZEk3SWdoaGpJVnZDUDhlMEF1dWdxYTYxRTlWU2hFNnNwT0FyWnFPeVRoNUZlNUxOZk44R3lpaWx2WEFtX3hONDJOM0ZGdV9FOFJpRENmVUVDbkZ4SHEtbi1CT0tqZGlEMUJ6bHFkc0NmV19JRGJFd1lZVEVyYmswM3FpT19mMlFLMFN4cUNlX0dqbVRqWWVJcE0?oc=5" target="_blank">Why Biohaven Stock Was Rocking the Market This Week</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNWEdaZzUzMjY4eU4wSVk3SjB3YUZtNmZtU2VkU1ZEOE1QdWpHYVAwZ2JVUU1VWWkyNGhhOEQ5dlFTSXF2ODNVdGpsX2FtZ3pNSzNTWTI5Y2daOXFVT2lYakFWeFFydk52bHltOWg0VHpvV3pYWHpoaXczNWtVZmZQWlE2NF9ELXgzazZfdXpNX25FVnZqQldPeWFPUk0yZV9UNWNoVkZESk1BVGV4U1NTRjFuNEZzcFdBNzlfVg?oc=5" target="_blank">A Phase 3 Graves’ disease drug is part of a deal that could pay Biohaven up to $100 million.</a>&nbsp;&nbsp;<font color="#6f6f6f">Stock Titan</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeXZfUEJXYVZ2cmZkOVIzNWRZS3hNTGhtQWpFbnRmd2swNzhkYU0wc2FCQ1ZWWlNwN1pnZmxXdDUyTUc4eXBlS1NNZ0lkVUJFNTRKTEo3STlaYjdVTVJFT2lnSTZCNWpycXNUMXlOVmFNYmpNNjlwcVZ2NVd3VzhlOXZ1RTRBd1M5Zlc3eWZ3NUV0RFlNNkdnOEQ3ZmpRV05ZUmlTRVYtY3ZSTnhIQTlhTzRwcHNLNEJVUUtocUtTUUg?oc=5" target="_blank">Biohaven's cancer drug produced tumor shrinkage in heavily pretreated patients</a>&nbsp;&nbsp;<font color="#6f6f6f">Stock Titan</font>
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPNzBZZmFnNWpndlRtdW0tX2FlNkhsLWZBM0pwOGhhWlNNczBVVy1DZDUyMXF3UEN5d2dNRHBKV0djWnhmTG9PTDFPZkthd2cyZXlHVVF5MnBzSG5SUUhOajhqUVk3UWZjV1FsZHN2ZkJzd0pEbXA1b3VEU29ZRFZ3M3FZNVk4OXg1X2JEUjVDMVU1cDZhbC1N?oc=5" target="_blank">BHV-7000 for Bipolar Disorder Fails in Phase 2/3 Trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Psychiatric Times</font>
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxOXy1PdEEzM1h0Z0xPc0ZtVTdMSjdENmpCOWlOMTBHN0VmMHloVVV4YUoySmJfYnR3Wks3V1R0NEdzUXJDVURFNEtmVkdIUHdWZDQtelJPc2VsYTFyM24zUGNZeG5nQ1RVQWJ1S2FRS1BRRExUNU9tU19DWGFvR0FlVW1JRmJKN3U5STE3NkRlWVk1OWJuc3h3QVFQLUpIWGp0T1NLaExxRDRTOFpTOVdFR21UODkwSk1ubndIaTh4VDlUWTBIcUF0cmQ0bXhUTWpSTDdYMjBDVWItVkhyNFV6ejJBeXNVYlluaHJlY3ZaUkRrRnJMbHc?oc=5" target="_blank">Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxQYUV4N1FFbUJHOHJHMWJ0QjZfUExxcnZFSzlxMlFOZENHZWZzRHFSS21LVnVzS2tuZWdlQ1plUnl3cDhYZk9Xc0RzdkFSSjVqWWJIanA4cm5ZU3U5aFNWcnF2Rk1LN3JXX01LRVJKVEp3UXRYLTVrUVlicFd3T0k0eWJXRFZNWHJPTDNaUmR5MFljWWd6S05wNGhPS0Y5UWRreXBlc1BsbGZVZXlVTkZrRDBWcjBLN09rUnFHU2xZLVd6TzdFMkxpZGhlekttU2IzbVE2VmFZRzVoZWw3X0h2aHJIUGtNLU9uSmpZamFwNndnUkxQamRYZnlZUnpNaV9uZFdPbDV3Umw0bUhYSTQ3TG4teE92ektkZ1VwZVE1bDBzNWQ1dmVtd3NmWnhPNF9ldE9Ca1l3?oc=5" target="_blank">Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPckoxd2NmUHNoaUJpQXh5cGg4OFNobnFwSkFVQkplTmEzTWJBTllPVG51SmRLZGwzUXl1UU5KUUdpYTQyTkJSMDdKZHItNjFDTDFuWjFCTl9pTlBGZnllakJYQk1sRUtWWVZjQzVKNnlEWWhBZGFybTNYeU1PbFFDQjBhMnJaM20wUmVLZi03TXlwdGVRYjZlX2pwd1hWTnltQVNtbGF2LU1NdVJ0WGRBTkVlYmVCSmhmd0tN?oc=5" target="_blank">Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven</a>&nbsp;&nbsp;<font color="#6f6f6f">Stock Titan</font>
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNdlB1SlFBNWNvSHNtT1k5ZDZndEtGbkt0alZJWjdUNm5ES25wek40TEg5NU9TUjFLS1lKd3Z4RHRDLVFnRjdWa1diMzNmOWNrNlk5U0JhdFRQZ0hZS1dydUZKQVQ0MU9JUGhuTS1ZRjhlZVY5NTdoNVB3VEpRMWI2b2doTjZIRHU4Mm9aSWVYaEl4TXNMQzlBamsyZjZEZw?oc=5" target="_blank">Biohaven seeks drug approval for rare neurological disorder</a>&nbsp;&nbsp;<font color="#6f6f6f">Hartford Business Journal</font>
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxPci1idkJsN3JrM1plOTVpV2FGUGFOTzd3b2RZS1ltd2pLdks0U2xPZnRhTnlzaTRUcFRvRmJLdVc0NHctLWRDdk0taTFkSGxYNXJiNWtUTFdGQUpDbEMxZld3WVYwZGZ3dURwckhpSko3QjF2dGk0dUVxV2NuTHpvVmdDZHhfVGlOSUxqMGNpZW9Ydm9pT2dvdnBTd3IyTEJPZmd3S2Fpck55emt1QjM0dVlCVXMxRFFsTi05OUZKd1U1dXNZXzJsdnI5WDE2UU5jeEdYb0xXTk12TE5ZUUhrNm9VeGdNaTJfUElYWVBLZVFyR3ZfV21SbkswUm1wVFozV3Vfdg?oc=5" target="_blank">U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>